%0 Journal Article
%T Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases
%A Peter J O&rsquo
%A Brien
%A Rajeev Ramanathan
%A Jonathan M Yingling
%A Jose Baselga
%J Biologics: Targets and Therapy
%D 2008
%I Dove Medical Press
%X Peter J O¡¯Brien1, Rajeev Ramanathan2, Jonathan M Yingling1, Jose Baselga3, Mace L Rothenberg4, Michael Carducci5, Thomas Daly1, Dorothy Adcock2, Michael Lahn11Eli Lilly and Company Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA; 2Esoterix Coagulation, Aurora, CO, USA; 3Vall d¡¯Hebron University Hospital, Barcelona, Spain; 4Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USAAbstract: Transforming growth factor beta (TGF¦Â) plays an important role in cancer, but accurate measurement of circulating TGF¦Â is complicated by the high TGF¦Â content of platelets which can release TGF¦Â ex vivo. We evaluated the use of citrate-theophylline-adenosine-dipyridamole (CTAD) tubes to reduce preanalytical variation in TGF¦Â measurements caused by ex vivo platelet activation. CTAD substantially reduced ex vivo platelet activation relative to traditional plasma collections in normal donors, which correlated with a decrease in measured TGF¦Â levels. We show that TGF¦Â levels are elevated in the majority of cancer patients with skeletal metastases, and that within-patient variability of these levels is relatively low over several weeks. Patients with elevated TGF¦Â could be subdivided into groups with or without evidence of platelet contribution to measured TGF¦Â levels. The use of CTAD tubes allows a better determination of a patient¡¯s TGF¦Â status, and may improve classification of patients with oncologic disease.Keywords: TGF¦Â, cancer, biomarker, CTAD
%U http://www.dovepress.com/analysis-and-variability-of-tgfbeta-measurements-in-cancer-patients-wi-a2305